Nordic Life Sciences AS (NLS) is a leading Nordic biopharmaceutical research and development company licensed by the Danish Medicines Agency. We are dedicated to the discovery and development of novel, high-value plant-derived compounds with verified therapeutic potential, supported by rigorous laboratory research, a pharmaceutical quality mindset, and a growing network of scientific collaborations and proprietary research projects.
A core part of our pharmaceutical-grade approach is medical cannabis production using advanced hydroponic cultivation systems. For NLS, hydroponics is not simply a cultivation preference–it is a deliberate operational foundation that enhances process control, repeatability, and contamination risk management. This enables consistent, high-quality plant material and supports the scientific rigor and reproducibility required for evidence-based development.
By continuously adopting the latest cultivation and analytical technologies, NLS aims to remain at the forefront of a rapidly evolving global market–advancing safe, scientifically grounded solutions to pressing health challenges, including chronic inflammation, neurological disorders, immune system dysfunction, and related therapeutic areas.
Nordic Life Sciences A/S is a Denmark-based life sciences company dedicated to pharmaceutical-grade research and innovation in plant-derived science. Built on Nordic standards of governance, scientific rigor, and regulatory discipline, the company develops high-quality solutions through structured research, validated processes, and strict quality control.
With a centralized and transparent corporate structure, Nordic Life Sciences ensures regulatory compliance, strong intellectual property protection, and scalable operations.
Our mission is clear: to combine nature and science in a responsible, compliant, and globally scalable life sciences platform.
Nordic Life Sciences A/S is a Denmark-based life sciences company dedicated to pharmaceutical-grade research and innovation in plant-derived science. Built on Nordic standards of governance, scientific rigor, and regulatory discipline, the company develops high-quality solutions through structured research, validated processes, and strict quality control. With a centralized and transparent corporate structure, Nordic Life Sciences ensures regulatory compliance, strong intellectual property protection, and scalable operations. Our mission is clear: to combine nature and science in a responsible, compliant, and globally scalable life sciences platform.
Nordic Life Sciences operates within a structured legal and governance framework aligned with Danish and European public market standards. Legal matters are supported by an appointed Danish law firm with expertise in finance and healthcare regulation. All operations are conducted in full compliance with Danish legislation and applicable EU regulatory requirements. Financial reporting and oversight are provided by a Chartered Accountant in Denmark. The Company maintains structured internal controls and prepares its financial reporting in compliance with IFRS, ensuring transparency, accountability, and investor confidence. Nordic Life Sciences is committed to capital markets-ready governance standards in preparation for public market participation.
Chairman of the Board / CEO
Erik Sundt is an experienced entrepreneur and executive with over 25 years in international business. He has worked across continents to source and develop natural herbs for the life sciences industry and has extensive experience in global commodity trading and strategic business development.
Chief Financial Officer
Zilvinas is a capital markets-oriented CFO, he has more than 12 years of experience in the investment banking, capital markets, asset management and corporate finance in Norway as well as held several outsourced CFO functions. He is also a CFA® charterholder from CFA Institute. Zilvinas has been also working as a financial consultant and played various roles in establishing two banks in Lithuania, Fintechs, asset management companies and participated in numerous capital raisings, IPOs and M&A in the Nordics.
QA Specialist and Board Member
Chief Quality Assurance
Rime Bahij is an esteemed researcher specializing in the field of medical cannabis. With extensive knowledge in analytical chemistry, she has developed methodologies to explore the properties and effects of cannabis on human health. Her work bridges the gap between basic research and clinical application, making significant strides in understanding cannabis' therapeutic potentials.
Board Member
Paal is a serial entrepreneur with a track record of success in building businesses in various US, Europe, and Asia industries.Paal has significant cannabis industry knowledge and a network of relationships in business and finance.
Board Member
Mikael is a serial entrepeneur specialising in team building while planning for strategy and future growth. Mikael has a strong background in finance and cultivating business relationships
Chairman of the Advisory Board
Rainer is one of the worlds foremost GMP experts with more than 360 audits completed on Cannabis companies worldwide.Rainer represents several big pharmaceutical companies such as Merck, Bayer, Sanofi and Siemens to mentioned a few.
Controller
Heidi Manley Rosholm, a former bank executive and
seasoned business advisor, brings extensive experience
in finance, corporate strategy, and business
development. As Controller, she ensures financial
precision, strategic alignment, and disciplined
execution across all operations.
Chief Master Grower
Anders Olofsson Master Grower. A cannabis genetics expert and a specialist in the production of flowers and derivative products such as hash, pollens, oils, food products, and cosmetics. He is a former director, founder and head grower of Medical Cannabis Denmark Aps and has subsequently worked as a freelance consultant within the industry.
QA Specialist
Claudia Guadalupe Ricci is an Investment Portfolio QA Project Manager at Novo Nordisk, based in Copenhagen. She excels in leading cross-functional projects, ensuring quality, and driving process improvements, with a background from Universidad Nacional del Litoral.
The Company has a forward-facing vision which aligns with Scandinavian public health values, evidence-led research, and academic collaboration. The corporate strategy includes:
• Nordic-focused investment decks and literature;
• Partnerships with research universities;
• Market entry into pharmaceutical supply and nutraceutical development chains.
The company’s financial and tax affairs are managed by a UK-based accountancy and advisory firm with a century-long heritage and national recognition for excellence. The firm provides comprehensive support in international tax, group structuring, and regulatory compliance, ensuring: Accurate and transparent financial reporting; Full adherence to UK and international tax disclosure requirements; Effective liaison with relevant regulatory and tax authorities in the United Kingdom and Denmark. This framework upholds investor confidence through strong financial governance, transparent record-keeping, and corporate accountability.
The Company has a forward-facing vision which aligns with Scandinavian public health values, evidence-led research, and academic collaboration. The corporate strategy includes:
• Nordic-focused investment decks and literature;
• Partnerships with research universities;
• Market entry into pharmaceutical supply and nutraceutical development chains.
Our operational and scientific structure draws on cross-border strengths: Danish precision in R&D, UK excellence in legal and financial governance, and a branding and regulatory strategy aligned with Nordic life sciences expectations.
Nordic Life Cciences: strategic analysis of the european medical cannabis market
Nordic Life Sciences AS is a Nordic biopharmaceutical R&D company focused on discovering and developing high-value plant-derived compounds with therapeutic potential.
The company’s stated focus includes areas like chronic inflammation, chronic pain, immune system dysfunction, neurological disorders, and related therapeutic applications.
Nordic Life Sciences states that its initiatives are fully compliant with EU and Danish regulations and that none of its projects involve restricted or controlled substances.
The site highlights a growing network of collaborations and joint ventures with academic institutions for independent validation as part of its R&D approach.
The company describes UK-based legal oversight (General Counsel in London) plus Danish local counsel and certified Danish audit/accounting support, aimed at ensuring regulatory compliance and auditability.
